Neurocrine sheds 200 Indiplon reps

Share this article:
Neurocrine Biosciences has laid off its entire 200-person sales force, the San Diego firm said. The decision follows Pfizer's ending of its marketing partnership with Neurocrine after the latter lost approval for insomnia drug Indiplon, and Pfizer lost US patent protection for Zoloft.

Neurocrine was then unable to acquire a product to keep the reps busy as it continues to seek FDA approval for Indiplon.

Neurocrine plans to meet with the FDA to finalize plans for the resubmission of each Indiplon NDA and to commercialize Indiplon quickly upon approval.
Neurocrine also said it is reviewing other possible future partnerships.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Pharmaceutical

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.